For the symptomatic improvement of walking in adult patients with multiple sclerosis with walking disability.
It should only be prescribed by (or following consultation with) clinicians who are experienced in the management of multiple sclerosis and who are knowledgeable of the efficacy and safety profile of FAMPYRA and are able to discuss the benefits/risks with patients.
Further information is available from the Fampyra in Motion program.